Report cover image

Global Virus Like Particles Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 196 Pages
SKU # APRC20361538

Description

Summary

According to APO Research, The global Virus Like Particles market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Virus Like Particles is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Virus Like Particles is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Virus Like Particles is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Virus Like Particles is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Virus Like Particles include Agilvax, Allergy Therapeutics, ANGANY Genetics, CPL Biologicals, Cytos Biotechnology, GeoVax Labs, Medicago, MedImmune and Novavax, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Virus Like Particles, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Virus Like Particles, also provides the sales of main regions and countries. Of the upcoming market potential for Virus Like Particles, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Virus Like Particles sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Virus Like Particles market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Virus Like Particles sales, projected growth trends, production technology, application and end-user industry.

Virus Like Particles Segment by Company

Agilvax
Allergy Therapeutics
ANGANY Genetics
CPL Biologicals
Cytos Biotechnology
GeoVax Labs
Medicago
MedImmune
Novavax
Serum Institute of India
TechnoVax
Xiamen Innovax Biotech
GlaxoSmithKline
Merck
Takeda
Virus Like Particles Segment by Type

Hepatitis B Virus
Adeno-Associated Virus
Hepatitis C Virus
HIV
Others
Virus Like Particles Segment by Application

Therapeutic and Imaging Agents
Mycoviruses
Vaccines
Virus Research
Others
Virus Like Particles Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Like Particles market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus Like Particles and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Like Particles.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Virus Like Particles in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Virus Like Particles manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Virus Like Particles sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

196 Pages
1 Market Overview
1.1 Product Definition
1.2 Virus Like Particles Market by Type
1.2.1 Global Virus Like Particles Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Hepatitis B Virus
1.2.3 Adeno-Associated Virus
1.2.4 Hepatitis C Virus
1.2.5 HIV
1.2.6 Others
1.3 Virus Like Particles Market by Application
1.3.1 Global Virus Like Particles Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Therapeutic and Imaging Agents
1.3.3 Mycoviruses
1.3.4 Vaccines
1.3.5 Virus Research
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Virus Like Particles Market Dynamics
2.1 Virus Like Particles Industry Trends
2.2 Virus Like Particles Industry Drivers
2.3 Virus Like Particles Industry Opportunities and Challenges
2.4 Virus Like Particles Industry Restraints
3 Global Market Growth Prospects
3.1 Global Virus Like Particles Revenue Estimates and Forecasts (2020-2031)
3.2 Global Virus Like Particles Revenue by Region
3.2.1 Global Virus Like Particles Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Virus Like Particles Revenue by Region (2020-2025)
3.2.3 Global Virus Like Particles Revenue by Region (2026-2031)
3.2.4 Global Virus Like Particles Revenue Market Share by Region (2020-2031)
3.3 Global Virus Like Particles Sales Estimates and Forecasts 2020-2031
3.4 Global Virus Like Particles Sales by Region
3.4.1 Global Virus Like Particles Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Virus Like Particles Sales by Region (2020-2025)
3.4.3 Global Virus Like Particles Sales by Region (2026-2031)
3.4.4 Global Virus Like Particles Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Virus Like Particles Revenue by Manufacturers
4.1.1 Global Virus Like Particles Revenue by Manufacturers (2020-2025)
4.1.2 Global Virus Like Particles Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Virus Like Particles Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Virus Like Particles Sales by Manufacturers
4.2.1 Global Virus Like Particles Sales by Manufacturers (2020-2025)
4.2.2 Global Virus Like Particles Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Virus Like Particles Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Virus Like Particles Sales Price by Manufacturers (2020-2025)
4.4 Global Virus Like Particles Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Virus Like Particles Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Virus Like Particles Manufacturers, Product Type & Application
4.7 Global Virus Like Particles Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Virus Like Particles Market CR5 and HHI
4.8.2 2024 Virus Like Particles Tier 1, Tier 2, and Tier 3
5 Virus Like Particles Market by Type
5.1 Global Virus Like Particles Revenue by Type
5.1.1 Global Virus Like Particles Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Virus Like Particles Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Virus Like Particles Revenue Market Share by Type (2020-2031)
5.2 Global Virus Like Particles Sales by Type
5.2.1 Global Virus Like Particles Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Virus Like Particles Sales by Type (2020-2031) & (K Units)
5.2.3 Global Virus Like Particles Sales Market Share by Type (2020-2031)
5.3 Global Virus Like Particles Price by Type
6 Virus Like Particles Market by Application
6.1 Global Virus Like Particles Revenue by Application
6.1.1 Global Virus Like Particles Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Virus Like Particles Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Virus Like Particles Revenue Market Share by Application (2020-2031)
6.2 Global Virus Like Particles Sales by Application
6.2.1 Global Virus Like Particles Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Virus Like Particles Sales by Application (2020-2031) & (K Units)
6.2.3 Global Virus Like Particles Sales Market Share by Application (2020-2031)
6.3 Global Virus Like Particles Price by Application
7 Company Profiles
7.1 Agilvax
7.1.1 Agilvax Comapny Information
7.1.2 Agilvax Business Overview
7.1.3 Agilvax Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Agilvax Virus Like Particles Product Portfolio
7.1.5 Agilvax Recent Developments
7.2 Allergy Therapeutics
7.2.1 Allergy Therapeutics Comapny Information
7.2.2 Allergy Therapeutics Business Overview
7.2.3 Allergy Therapeutics Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Allergy Therapeutics Virus Like Particles Product Portfolio
7.2.5 Allergy Therapeutics Recent Developments
7.3 ANGANY Genetics
7.3.1 ANGANY Genetics Comapny Information
7.3.2 ANGANY Genetics Business Overview
7.3.3 ANGANY Genetics Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 ANGANY Genetics Virus Like Particles Product Portfolio
7.3.5 ANGANY Genetics Recent Developments
7.4 CPL Biologicals
7.4.1 CPL Biologicals Comapny Information
7.4.2 CPL Biologicals Business Overview
7.4.3 CPL Biologicals Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 CPL Biologicals Virus Like Particles Product Portfolio
7.4.5 CPL Biologicals Recent Developments
7.5 Cytos Biotechnology
7.5.1 Cytos Biotechnology Comapny Information
7.5.2 Cytos Biotechnology Business Overview
7.5.3 Cytos Biotechnology Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Cytos Biotechnology Virus Like Particles Product Portfolio
7.5.5 Cytos Biotechnology Recent Developments
7.6 GeoVax Labs
7.6.1 GeoVax Labs Comapny Information
7.6.2 GeoVax Labs Business Overview
7.6.3 GeoVax Labs Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 GeoVax Labs Virus Like Particles Product Portfolio
7.6.5 GeoVax Labs Recent Developments
7.7 Medicago
7.7.1 Medicago Comapny Information
7.7.2 Medicago Business Overview
7.7.3 Medicago Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Medicago Virus Like Particles Product Portfolio
7.7.5 Medicago Recent Developments
7.8 MedImmune
7.8.1 MedImmune Comapny Information
7.8.2 MedImmune Business Overview
7.8.3 MedImmune Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 MedImmune Virus Like Particles Product Portfolio
7.8.5 MedImmune Recent Developments
7.9 Novavax
7.9.1 Novavax Comapny Information
7.9.2 Novavax Business Overview
7.9.3 Novavax Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Novavax Virus Like Particles Product Portfolio
7.9.5 Novavax Recent Developments
7.10 Serum Institute of India
7.10.1 Serum Institute of India Comapny Information
7.10.2 Serum Institute of India Business Overview
7.10.3 Serum Institute of India Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Serum Institute of India Virus Like Particles Product Portfolio
7.10.5 Serum Institute of India Recent Developments
7.11 TechnoVax
7.11.1 TechnoVax Comapny Information
7.11.2 TechnoVax Business Overview
7.11.3 TechnoVax Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 TechnoVax Virus Like Particles Product Portfolio
7.11.5 TechnoVax Recent Developments
7.12 Xiamen Innovax Biotech
7.12.1 Xiamen Innovax Biotech Comapny Information
7.12.2 Xiamen Innovax Biotech Business Overview
7.12.3 Xiamen Innovax Biotech Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 Xiamen Innovax Biotech Virus Like Particles Product Portfolio
7.12.5 Xiamen Innovax Biotech Recent Developments
7.13 GlaxoSmithKline
7.13.1 GlaxoSmithKline Comapny Information
7.13.2 GlaxoSmithKline Business Overview
7.13.3 GlaxoSmithKline Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 GlaxoSmithKline Virus Like Particles Product Portfolio
7.13.5 GlaxoSmithKline Recent Developments
7.14 Merck
7.14.1 Merck Comapny Information
7.14.2 Merck Business Overview
7.14.3 Merck Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Merck Virus Like Particles Product Portfolio
7.14.5 Merck Recent Developments
7.15 Takeda
7.15.1 Takeda Comapny Information
7.15.2 Takeda Business Overview
7.15.3 Takeda Virus Like Particles Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Takeda Virus Like Particles Product Portfolio
7.15.5 Takeda Recent Developments
8 North America
8.1 North America Virus Like Particles Market Size by Type
8.1.1 North America Virus Like Particles Revenue by Type (2020-2031)
8.1.2 North America Virus Like Particles Sales by Type (2020-2031)
8.1.3 North America Virus Like Particles Price by Type (2020-2031)
8.2 North America Virus Like Particles Market Size by Application
8.2.1 North America Virus Like Particles Revenue by Application (2020-2031)
8.2.2 North America Virus Like Particles Sales by Application (2020-2031)
8.2.3 North America Virus Like Particles Price by Application (2020-2031)
8.3 North America Virus Like Particles Market Size by Country
8.3.1 North America Virus Like Particles Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Virus Like Particles Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Virus Like Particles Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Virus Like Particles Market Size by Type
9.1.1 Europe Virus Like Particles Revenue by Type (2020-2031)
9.1.2 Europe Virus Like Particles Sales by Type (2020-2031)
9.1.3 Europe Virus Like Particles Price by Type (2020-2031)
9.2 Europe Virus Like Particles Market Size by Application
9.2.1 Europe Virus Like Particles Revenue by Application (2020-2031)
9.2.2 Europe Virus Like Particles Sales by Application (2020-2031)
9.2.3 Europe Virus Like Particles Price by Application (2020-2031)
9.3 Europe Virus Like Particles Market Size by Country
9.3.1 Europe Virus Like Particles Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Virus Like Particles Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Virus Like Particles Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Virus Like Particles Market Size by Type
10.1.1 China Virus Like Particles Revenue by Type (2020-2031)
10.1.2 China Virus Like Particles Sales by Type (2020-2031)
10.1.3 China Virus Like Particles Price by Type (2020-2031)
10.2 China Virus Like Particles Market Size by Application
10.2.1 China Virus Like Particles Revenue by Application (2020-2031)
10.2.2 China Virus Like Particles Sales by Application (2020-2031)
10.2.3 China Virus Like Particles Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Virus Like Particles Market Size by Type
11.1.1 Asia Virus Like Particles Revenue by Type (2020-2031)
11.1.2 Asia Virus Like Particles Sales by Type (2020-2031)
11.1.3 Asia Virus Like Particles Price by Type (2020-2031)
11.2 Asia Virus Like Particles Market Size by Application
11.2.1 Asia Virus Like Particles Revenue by Application (2020-2031)
11.2.2 Asia Virus Like Particles Sales by Application (2020-2031)
11.2.3 Asia Virus Like Particles Price by Application (2020-2031)
11.3 Asia Virus Like Particles Market Size by Country
11.3.1 Asia Virus Like Particles Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Virus Like Particles Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Virus Like Particles Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Virus Like Particles Market Size by Type
12.1.1 SAMEA Virus Like Particles Revenue by Type (2020-2031)
12.1.2 SAMEA Virus Like Particles Sales by Type (2020-2031)
12.1.3 SAMEA Virus Like Particles Price by Type (2020-2031)
12.2 SAMEA Virus Like Particles Market Size by Application
12.2.1 SAMEA Virus Like Particles Revenue by Application (2020-2031)
12.2.2 SAMEA Virus Like Particles Sales by Application (2020-2031)
12.2.3 SAMEA Virus Like Particles Price by Application (2020-2031)
12.3 SAMEA Virus Like Particles Market Size by Country
12.3.1 SAMEA Virus Like Particles Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Virus Like Particles Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Virus Like Particles Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Virus Like Particles Value Chain Analysis
13.1.1 Virus Like Particles Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Virus Like Particles Production Mode & Process
13.2 Virus Like Particles Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Virus Like Particles Distributors
13.2.3 Virus Like Particles Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.